Medicure Inc (MPH) - Total Liabilities
Based on the latest financial reports, Medicure Inc (MPH) has total liabilities worth CA$11.02 Million CAD (≈ $7.97 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Medicure Inc to see how much of total assets are deployed in long-term investments.
Medicure Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how Medicure Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Medicure Inc (MPH) total assets.
Medicure Inc Competitors by Total Liabilities
The table below lists competitors of Medicure Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alticast Corporation
KQ:085810
|
Korea | ₩30.34 Billion |
|
Fabrity Holding S.A.
WAR:FAB
|
Poland | zł13.15 Million |
|
DEER HORN METS
F:G1J
|
Germany | €3.30 Million |
|
CodeMill AB
ST:CDMIL
|
Sweden | Skr22.14 Million |
|
TMK Energy Ltd
AU:TMK
|
Australia | AU$532.78K |
|
Substrate AI S.A.
MC:SAI
|
Spain | €23.32 Million |
|
Guandian Defense Technology Co. Ltd. A
SHG:688287
|
China | CN¥111.81 Million |
|
Alarko Gayrimenkul Yatirim Ortakligi AS
IS:ALGYO
|
Turkey | TL6.36 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Medicure Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Medicure Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medicure Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medicure Inc (2000–2025)
The table below shows the annual total liabilities of Medicure Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$12.04 Million ≈ $8.71 Million |
+35.27% |
| 2024-12-31 | CA$8.90 Million ≈ $6.44 Million |
+9.04% |
| 2023-12-31 | CA$8.16 Million ≈ $5.90 Million |
-8.21% |
| 2022-12-31 | CA$8.89 Million ≈ $6.43 Million |
-11.04% |
| 2021-12-31 | CA$10.00 Million ≈ $7.23 Million |
-32.94% |
| 2020-12-31 | CA$14.91 Million ≈ $10.78 Million |
-2.83% |
| 2019-12-31 | CA$15.34 Million ≈ $11.10 Million |
-23.93% |
| 2018-12-31 | CA$20.17 Million ≈ $14.59 Million |
-58.18% |
| 2017-12-31 | CA$48.22 Million ≈ $34.88 Million |
-72.56% |
| 2016-12-31 | CA$175.77 Million ≈ $127.15 Million |
+946.52% |
| 2015-12-31 | CA$16.80 Million ≈ $12.15 Million |
+60.39% |
| 2014-12-31 | CA$10.47 Million ≈ $7.57 Million |
+10.41% |
| 2013-12-31 | CA$9.48 Million ≈ $6.86 Million |
+22.37% |
| 2012-12-31 | CA$7.75 Million ≈ $5.61 Million |
+18.07% |
| 2011-12-31 | CA$6.56 Million ≈ $4.75 Million |
-79.53% |
| 2010-12-31 | CA$32.07 Million ≈ $23.20 Million |
+3.68% |
| 2009-12-31 | CA$30.93 Million ≈ $22.37 Million |
+6.30% |
| 2008-12-31 | CA$29.10 Million ≈ $21.05 Million |
-29.65% |
| 2007-12-31 | CA$41.36 Million ≈ $29.92 Million |
+62.33% |
| 2006-12-31 | CA$25.48 Million ≈ $18.43 Million |
+1449.52% |
| 2005-12-31 | CA$1.64 Million ≈ $1.19 Million |
-39.83% |
| 2004-12-31 | CA$2.73 Million ≈ $1.98 Million |
+234.25% |
| 2003-12-31 | CA$817.57K ≈ $591.42K |
+131.01% |
| 2002-12-31 | CA$353.91K ≈ $256.01K |
-9.18% |
| 2001-12-31 | CA$389.66K ≈ $281.88K |
-31.65% |
| 2000-12-31 | CA$570.08K ≈ $412.38K |
-- |
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more